LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has signed a research agreement with Dr. Peter Brooks of the Maine Medical Center, a specialist in the mechanisms that regulate angiogenesis, tumor growth and metastasis, to explore novel targets and antibodies associated with targeting cancer stem cells (CSCs). The collaboration is designed to produce novel antibodies using the Company’s proprietary CSCs isolated from glioblastoma patients to target epitopes primarily present on CSCs. This could enhance the understanding of the expression and function of molecular signatures in CSCs that might help to better define them, potentially enabling more effective approaches for identifying and treating a wide range of malignant human tumors.
